María Fernanda Román

Ms. María Fernanda Román

Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Angel León-BuitimeaAngel León-Buitimea
Angel León-Buitimea
CCCésar Rodolfo Garza Cárdenas
César Rodolfo Garza Cárdenas
María Fernanda RománMaría Fernanda Román
María Fernanda Román
CRCésar Agustín Ramírez-Díaz
César Agustín Ramírez-Díaz
MUMartha Ulloa-Ramírez
Martha Ulloa-Ramírez
JMJosé Ruben Morones-Ramírez
José Ruben Morones-Ramírez
Since the discovery of antibiotics, humanity has been able to cope with the battle against bacterial infections. However, the inappropriate use of antibiotics, the lack of innovation in therapeutic agents, and other factors have allowed the emergence of new bacterial strains resistant to multiple antibiotic treatments, causing a crisis in the health sector. Furthermore, the World Health Organization has listed a series of pathogens (ESKAPE group) that have acquired new and varied resistance to different antibiotics families. Therefore, the scientific community has prioritized designing and developing novel treatments to combat these ESKAPE pathogens and other emergent multidrug-resistant bacteria. One of the solutions is the use of combinatorial therapies. Combinatorial therapies seek to enhance the effects of individual treatments at lower doses, bringing the advantage of being, in most cases, much less harmful to patients. Among the new developments in combinatorial therapies, nanomaterials have gained significant interest. Some of the most promising nanotherapeutics include polymers, inorganic nanoparticles, and antimicrobial peptides due to their bactericidal and nanocarrier properties. Therefore, this review focuses on discussing the state-of-the-art of the most significant advances and concludes with a perspective on the future developments of nanotherapeutic combinatorial treatments that target bacterial infections.